Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting PDGF signaling of cancer-associated fibroblasts blocks feedback activation of HIF-1α and tumor progression of clear cell ovarian cancer.
Mori Y, Okimoto Y, Sakai H, Kanda Y, Ohata H, Shiokawa D, Suzuki M, Yoshida H, Ueda H, Sekizuka T, Tamura R, Yamawaki K, Ishiguro T, Mateos RN, Shiraishi Y, Yatabe Y, Hamada A, Yoshihara K, Enomoto T, Okamoto K. Mori Y, et al. Among authors: hamada a. Cell Rep Med. 2024 May 21;5(5):101532. doi: 10.1016/j.xcrm.2024.101532. Epub 2024 Apr 25. Cell Rep Med. 2024. PMID: 38670097 Free PMC article.
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.
Yagishita S, Nishikawa T, Yoshida H, Shintani D, Sato S, Miwa M, Suzuki M, Yasuda M, Ogitani Y, Jikoh T, Yonemori K, Hasegawa K, Hamada A. Yagishita S, et al. Among authors: hamada a. Clin Cancer Res. 2023 Jun 13;29(12):2239-2249. doi: 10.1158/1078-0432.CCR-22-3861. Clin Cancer Res. 2023. PMID: 36976261
Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report.
Torasawa M, Yoshida T, Shiraishi K, Goto N, Ueno T, Ichikawa H, Yagishita S, Kohsaka S, Goto Y, Yatabe Y, Hamada A, Mano H, Ohe Y. Torasawa M, et al. Among authors: hamada a. JTO Clin Res Rep. 2024 Feb 28;5(4):100657. doi: 10.1016/j.jtocrr.2024.100657. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38706977 Free PMC article.
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.
Yamamoto G, Tanaka K, Kamata R, Saito H, Yamamori-Morita T, Nakao T, Liu J, Mori S, Yagishita S, Hamada A, Shinno Y, Yoshida T, Horinouchi H, Ohe Y, Watanabe SI, Yatabe Y, Kitai H, Konno S, Kobayashi SS, Ohashi A. Yamamoto G, et al. Among authors: hamada a. Cancer Lett. 2024 Dec 24;611:217414. doi: 10.1016/j.canlet.2024.217414. Online ahead of print. Cancer Lett. 2024. PMID: 39725152 Free article.
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: hamada a. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma.
Kojima Y, Yoshida H, Okuya T, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Shimoi T, Tamura K, Tanase Y, Uno M, Ishikawa M, Arakaki M, Ichikawa H, Yagishita S, Hamada A, Fujiwara Y, Yonemori K, Kato T. Kojima Y, et al. Among authors: hamada a. Gynecol Oncol Rep. 2023 Nov 14;50:101302. doi: 10.1016/j.gore.2023.101302. eCollection 2023 Dec. Gynecol Oncol Rep. 2023. PMID: 38054200 Free PMC article.
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia.
Miyazaki B, Ueno T, Sugiyama M, Kojima S, Arakawa A, Tao K, Tanimura K, Shiraishi K, Yagishita S, Kohsaka S, Kato M, Kiyokawa N, Goto Y, Yatabe Y, Hamada A, Mano H, Ogawa C, Tanaka Y. Miyazaki B, et al. Among authors: hamada a. NPJ Precis Oncol. 2023 Dec 9;7(1):132. doi: 10.1038/s41698-023-00485-7. NPJ Precis Oncol. 2023. PMID: 38071343 Free PMC article.
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC.
Jo H, Yoshida T, Yagishita S, Ohuchi M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Takahashi K, Motoi N, Hamada A, Ohe Y. Jo H, et al. Among authors: hamada a. JTO Clin Res Rep. 2023 Feb 11;4(4):100474. doi: 10.1016/j.jtocrr.2023.100474. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37007867 Free PMC article.
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510).
Nishikawa T, Kakunaga S, Tamura K, Ando M, Ozaki T, Kawai A, Ueda T, Kawasaki M, Tomatsuri S, Okamura N, Kamikura M, Hamada A, Yoshida A, Hirakawa A, Shibata T, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: hamada a. Cancer. 2024 Nov 15;130(22):3836-3844. doi: 10.1002/cncr.35483. Epub 2024 Jul 30. Cancer. 2024. PMID: 39077795 Clinical Trial.
624 results